Community oncologists help refer appropriate patients to authorized treatment centers.
Presence of a complex karyotype did not affect progression-free or overall survival.
High prevalence of pathogenic/likely pathogenic variants supports wider testing.
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Survivors of NHL should be offered genetic counseling.
Further studies needed to look at relevance outside of the transplant-eligible population.
Emerging overall survival data show a benefit of this type of drug across a variety of patient subgroups.
Data could support regulatory, payer decision making.
A new study challenges the recommended use of cotesting for cervical cancer screening.